结核分枝桿菌检测市场:市场规模（按细分市场）、份额、监管、报销、预测（~2033）

结核病有两种感染方式:潜伏性结核病和活动性结核病。 在潜伏性结核病中，结核桿菌在体内保持休眠状态。 儘管大多数人没有表现出症状，但这些患者被认为有发生活动性结核感染的风险。 结核病可以透过多种检查来检测，包括结核皮肤试验（TST）、干扰素Gamma释放测定（IGRA）血液检查、核酸扩增检验（NAAT）、痰液涂片镜检和培养。 此外，胸部 X 光检查通常用于诊断结核感染。 多重抗药性结核病对全球结核病根除工作构成日益严重的威胁。 由于检测基础设施不一致以及实验室专家和临床医生的短缺，诊断很困难。 多重抗药性结核病被定义为至少对异烟□和利福平抗药性的结核分枝桿菌，而广泛抗药性结核病被定义为对更多药物抗药性，包括氟奎诺酮类药物以及三种注射（阿米卡星、卡那霉素、捲曲霉素）中的任何一种。

结核分枝桿菌诊断测试包括 IGRA 测试和结核分枝桿菌 NAAT 测试。

本报告深入了解全球结核分枝桿菌检测市场，提供竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响、区域和国家趋势等。

目录

结核病检测试剂市场现况及竞争状况

• 对主要产业趋势的见解
• 2015 年至 2033 年结核分枝桿菌检测按细分市场划分的市场总收入和市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• 结核病检测市场的SWOT分析
• 结核分枝桿菌检测市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Mycobacterium Tuberculosis Tests market for the year 2020 and beyond. The tuberculosis (TB) infection has two modes of existence, latent TB and active TB. For latent TB, the mycobacterium is dormant within the body. The majority of individuals do not exhibit symptoms, but these patients are considered to be at risk for developing an active TB infection. Tuberculosis can be detected by a number of different tests including the tuberculosis skin test (TST), blood tests of interferon gamma release assays (IGRA), nucleic acid amplification tests (NAATs), sputum smear microscopy tests, and culture tests. Additionally, chest x-Rays are also often used to help diagnose TB infection. Multidrug-resistant tuberculosis is an increasingly serious threat to the eradication of global TB. Hard to diagnose due to the inconsistent testing infrastructure and lack of laboratory specialists and clinicians. MDR-TB is defined as the TB bacilli being resistant to at least isoniazid and rifampicin, while XDR-TB is resistant to more medicaments including fluoroquinolone, and to one of the three injectable drugs (amikacin, kanamycin, and capreomycin).

The Mycobacterium Tuberculosis diagnostic tests include IGRA and Mycobacterium Tuberculosis NAAT tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Mycobacterium Tuberculosis Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Mycobacterium Tuberculosis Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Mycobacterium Tuberculosis Tests market.
• Competitive dynamics insights and trends provided for Mycobacterium Tuberculosis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Qiagen NV, Oxford Immunotec Ltd, Danaher Corp, Molbio Diagnostics Pvt Ltd, Hologic Inc, F. Hoffmann-La Roche Ltd, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Mycobacterium Tuberculosis Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Mycobacterium Tuberculosis Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Mycobacterium Tuberculosis Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Mycobacterium Tuberculosis Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Mycobacterium Tuberculosis Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable